- AuthorisedTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
This study looks at new treatments for advanced lung cancer that has become resistant to previous immune-boosting therapies. It compares a combination of N-803, tislelizumab, and docetaxel against docetaxel alone, aiming to see if the combination helps people live longer.
For: Advanced or Metastatic Non-Small Cell Lung CancerGermany · Hungary · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
This study is looking into a new combination treatment for bladder cancer that hasn't spread into the muscle. It combines a standard treatment, BCG, with a new experimental drug called N-803. The aim is to see if this new combination works better at getting rid of the cancer.
For: Non-Muscle Invasive Bladder CancerGermany